Biotech start-up TOLREMO closes CHF2,4 million financing round

19.09.2017 09:38

Related tags

ETH Hönggerberg

TOLREMO therapeutics’ aim is to prevent drug resistance in cancer therapy. The successful first financing round allows to advance drug discovery and development efforts. 

TOLREMO, a spin-off from ETH Zurich, announced today the completion of a fundraising with private investors of 2.4 million Swiss Francs. The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.

Dr. Stefanie Flückiger-Mangual, Chief Executive Officer and co-founder of TOLREMO, commented: “Cancer patients often respond favorably to modern therapies, but in many cases long-term survival is limited by the development of drug resistance. During several years of research at ETH Zurich, we discovered that, surprisingly, the development of drug resistance already starts early on following initiation of cancer therapy. We have developed a deep understanding of the molecular mechanisms involved in this and our goal is to intervene with these mechanisms in order to eradicate the seed of drug resistance and extend patient survival.”

TOLREMO’s science-based drug discovery and development pipeline is fueled by a unique drug screening platform for which a patent has been filed. In addition to discovering and developing novel anti-drug resistance molecules, the platform is also used to identify novel ways of combining approved drugs to prevent drug resistance in cancer therapy.

Dr. Isaac Kobrin, Chairman of the Board and a co-founder of TOLREMO, commented: “We believe that TOLREMO is poised to reach several key milestones in the development of novel cancer therapies within the next 12 to 18 months. The currently raised funds of 2.4 million Swiss Francs are expected to cover that period and prepare the grounds for the future growth of the company.”

TOLREMO is an ETH Spin-off and was founded in March 2017. The company is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where it is part of a dynamic scientific and entrepreneurial community. TOLREMO enjoys broad access to state-of-the-art ETH infrastructure including laboratory space and an industry standard robotic screening facility.

Picture: ETH Zürich / Alessandro Della Bella

(Press rekease)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Highlights TOLREMO therapeutics AG

Related News

Related tags

Read more about

More news about TOLREMO therapeutics AG
Please login or
register to use the
bookmark feature

Related News

Highlights TOLREMO therapeutics AG

Related tags

Read more about

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

 

Principal

18.01.2019
Editorial

Good times for pioneers

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS